Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TUMOROID: Pilot study of intratumoral osimertinib concentration in peritoneal and liver metastases of colorectal cancer
2022-003460-24Phase 4Completed
- Sponsor
- Radboud University Medical Center
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of osimertinib in colorectal cancer (CRC) and colorectal cancer liver metastasis (CRLM) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Intratumoral osimertinib concentration in peritoneal metastasis and liver metastasis. Started Nov 2022; status: completed.
02
Drugs
03
Conditions
colorectal cancer (CRC)colorectal cancer liver metastasis (CRLM)
Beyond the preview
Go deeper on 2022-003460-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003460-24.